14 results found.

Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineobla Clinical Trial using temozolomide; irinotecan hydrochloride; bevacizumab

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial.
temozolomide; irinotecan hydrochloride; bevacizumab

Medulloblastoma Clinical Trial using Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation

St. Jude Children's Research Hospital - Recruiting 3 years to 21 years.
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma.
Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation

Astrocytoma, Central Nervous System Tumor, Glioblastoma, Glioma, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Evaluation of the Natural History of Patients With Tumors of the Central Nervous System.

Untreated Childhood Medulloblastoma Clinical Trial using vincristine sulfate; cyclophosphamide; methotrexate; etoposide; carboplatin; laboratory biomarker analysis; cognitive assessment

Children's Oncology Group - Recruiting N/A to 47 Months.
- A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age.
vincristine sulfate; cyclophosphamide; methotrexate; etoposide; carboplatin; laboratory biomarker analysis; cognitive assessment

Brain Tumor, or Central Nervous System Tumor Clinical Trial using cisplatin; cyclophosphamide; lomustine; vincristine sulfate; radiation therapy

Children's Oncology Group - Recruiting 3 years to 21 years.
- A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial.
cisplatin; cyclophosphamide; lomustine; vincristine sulfate; radiation therapy

Neuroblastoma, or Medulloblastoma Clinical Trial using Nifurtimox; Cyclophosphamide; Topotecan

Spectrum Health Hospitals - Recruiting N/A to 21 years.
- A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma..
Nifurtimox; Cyclophosphamide; Topotecan

Neuroblastoma, Medulloblastoma, Brain Tumors, or Rare Tumors Clinical Trial using Guided Therapy- Pediatric Gene Analysis Platform

Spectrum Health Hospitals - Recruiting 13 Months or older.
- A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer.
Guided Therapy- Pediatric Gene Analysis Platform

Brain and Central Nervous System Tumors Clinical Trial

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas and Medulloblastoma/PNET of the Pediatric CNS.

High-risk Medulloblastoma Clinical Trial using Carboplatin + etoposide; Thiotepa; Cyclophosphamide + Busilvex

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting N/A to 5 years.
- Phase I / II Study of Sequential High-dose Chemotherapy With Stem Cell Support in Children Younger Than 5 Years of Age With High-risk Medulloblastoma.
Carboplatin + etoposide; Thiotepa; Cyclophosphamide + Busilvex

Neuroblastoma, or Medulloblastoma Clinical Trial using TPI 287

Spectrum Health Hospitals - Recruiting 12 Months to 30 years.
- A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma.
TPI 287

Medulloblastoma,, Rhabdomyosarcoma,, Neuroblastoma,, Hepatoblasto Clinical Trial using LDE225

Novartis - Recruiting 12 Months to 18 years.
- A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma.
LDE225

Brain and Central Nervous System Tumors Clinical Trial using cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 3 years to 30 years.
- Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).
cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

Medulloblastoma Clinical Trial using Bevacizumab; Thalidomide; Celecoxib; Fenofibric acid; Etoposide; Cyclophosphamide; Etoposide phosphate; Liposomal cytarabine

Medical University of Vienna - Recruiting N/A to 19 years.
- A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma.
Bevacizumab; Thalidomide; Celecoxib; Fenofibric acid; Etoposide; Cyclophosphamide; Etoposide phosphate; Liposomal cytarabine

Medulloblastoma, Brain Tumors, or Neuroectodermal Tumors, Primiti Clinical Trial using Etoposide, carboplatin, melphalan, cisplatin, thiotepa

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting N/A to 10 years.
- Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy.
Etoposide, carboplatin, melphalan, cisplatin, thiotepa